LOQTORZI
Clinical safety rating: caution
Comprehensive clinical and safety monograph for LOQTORZI (LOQTORZI).
LOQTORZI is a programmed death receptor-1 (PD-1) blocking antibody that binds to PD-1 and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response.
| Metabolism | LOQTORZI is a monoclonal antibody; it is expected to be degraded into small peptides and amino acids via general protein degradation pathways. No specific metabolic enzymes or pathways have been identified. |
| Excretion | Primarily proteolytic catabolism; minimal renal excretion (no intact antibody in urine); no biliary/fecal data due to lack of studies. |
| Half-life | Mean terminal elimination half-life is 25.5 days (range 16–32 days), supporting every-4-week dosing. |
| Protein binding | No specific binding to serum proteins; as a monoclonal antibody, it is not significantly protein-bound. |
| Volume of Distribution | Central Vd approximately 3.5–4.0 L; small distribution consistent with limited extravascular penetration. |
| Bioavailability | IV: 100% (not administered via other routes). |
| Onset of Action | IV: Clinical response observed after 2–4 cycles (6–12 weeks) in clinical trials. |
| Duration of Action | Duration of effect is prolonged due to long half-life; immune-mediated adverse events may persist for months after discontinuation. |
240 mg intravenously over 30 minutes every 2 weeks until disease progression or unacceptable toxicity.
| Dosage form | INJECTABLE |
| Renal impairment | No dose adjustment recommended for mild to moderate renal impairment (CrCl ≥30 mL/min). Insufficient data for severe renal impairment (CrCl <30 mL/min). |
| Liver impairment | No dose adjustment recommended for mild hepatic impairment (Child-Pugh A). Not studied in moderate or severe hepatic impairment (Child-Pugh B or C). |
| Pediatric use | Safety and efficacy not established in pediatric patients. |
| Geriatric use | No specific dose adjustment required based on age; monitor for immune-mediated adverse reactions. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for LOQTORZI (LOQTORZI).
| Breastfeeding | There are no data on the presence of toripalimab-tpzi in human milk, its effects on the breastfed child, or on milk production. Toripalimab-tpzi is a large monoclonal antibody that is likely to be excreted in human milk in small amounts, but the extent of absorption by the infant is unknown. Because of the potential for serious adverse reactions in nursing infants, including immune-mediated effects, advise women not to breastfeed during treatment with LOQTORZI and for at least 4 months after the last dose. The milk-to-plasma (M/P) ratio is not available for toripalimab-tpzi. |
| Teratogenic Risk | LOQTORZI (toripalimab-tpzi) is a humanized monoclonal antibody of the IgG4κ subclass targeting programmed death-1 (PD-1). Based on its mechanism of action, PD-1/PD-L1 inhibitors are known to have a risk of fetal harm when administered to pregnant women. Inhibition of the PD-1/PD-L1 pathway has been shown to alter maternal immune tolerance to the fetus, leading to an increased incidence of abortion, stillbirth, and preterm delivery in animal models. In human pregnancies, exposure during the first trimester may be associated with a theoretical risk of immune-mediated fetal loss, while second and third trimester exposure can cause fetal immune activation, potentially leading to neonatal immune dysfunction, including severe inflammatory reactions or graft-versus-host-like disease. There are no adequate and well-controlled studies in pregnant women. LOQTORZI should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. |
■ FDA Black Box Warning
No FDA black box warning is currently listed for LOQTORZI.
| Serious Effects |
None known.
| Precautions | ["Immune-mediated adverse reactions: including pneumonitis, colitis, hepatitis, endocrinopathies, nephritis, skin adverse reactions, and other immune-mediated adverse reactions.","Infusion-related reactions: may be severe or life-threatening.","Complications of allogeneic hematopoietic stem cell transplantation (HSCT): fatal and other serious complications may occur in patients who receive allogeneic HSCT before or after anti-PD-1 therapy.","Embryo-fetal toxicity: can cause fetal harm when administered to a pregnant woman."] |
Loading safety data…
| Fetal Monitoring | Monitor pregnant women exposed to LOQTORZI for potential adverse effects on the fetus, including fetal growth restriction, preterm birth, and signs of immune-mediated fetal or neonatal dysfunction. Perform serial fetal ultrasound assessments for growth and anatomy. Consider monitoring for maternal immune-related adverse events (e.g., pneumonitis, colitis, hepatitis, endocrinopathies) that could affect pregnancy outcome. After delivery, monitor neonates for immune-mediated reactions, such as cutaneous inflammation, hepatic dysfunction, or hematologic abnormalities. Administer routine prenatal care, including screening for gestational diabetes and hypertension, as these may be more prevalent with immunotherapy exposure. There are no specific fetal heart rate monitoring recommendations beyond standard obstetric practice. |
| Fertility Effects | There are no human data on the effect of toripalimab-tpzi on fertility. Based on its mechanism of action as a PD-1 inhibitor, it may theoretically impair fertility by altering immune regulation in the reproductive tract. In animal studies, there were no specific fertility assessments; however, no adverse effects on male or female reproductive organs were observed in general toxicology studies at clinically relevant exposures. The potential for temporary or permanent infertility due to immune-related ovarian or testicular dysfunction cannot be excluded. |